ISDA

Deposition Date 2015-03-13

Release Date 2015-04-29

Last Version Date 2024-02-28

Entry Detail

PDB ID:

4YQH

Keywords:

HYDROLASE/HYDROLASE INHIBITOR

Title:

2-[2-(4-Phenyl-1H-imidazol-2-yl)ethyl]quinoxaline (Sunovion Compound 14) co-crystallized with PDE10A

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.31 Å

R-Value Free:

0.30

R-Value Work:

0.23

R-Value Observed:

0.23

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Gene (Uniprot):PDE10A
Chain IDs:A, B
Chain Length:321
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q9Y233 EC:3.1.4.17

Ligand Molecules

4F7

Primary Citation

Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A.

Burdi, D.F, Campbell, J.E, Wang, J, Zhao, S, Zhong, H, Wei, J, Campbell, U, Shao, L, Herman, L, Koch, P, Jones, P.G, Hewitt, M.C.Show

Bioorg.Med.Chem.Lett. 25 1864 1868 (2015)

PMID: 25863433 DOI: 10.1016/j.bmcl.2015.03.050

Abstact

The design and synthesis of highly potent, selective orally bioavailable inhibitors of PDE10A is reported. Starting with an active compound of modest potency from a small focused screen, we were able to evolve this series to a lead molecule with high potency and selectivity versus other PDEs using structure-based design. A systematic refinement of ADME properties during lead optimization led to a lead compound with good half-life that was brain penetrant. Compound 39 was highly potent versus PDE10A (IC50=1.0 nM), demonstrated high selectivity (>1000-fold) against other PDEs and was efficacious when dosed orally in a rat model of psychosis, PCP-induced hyperlocomotion with an EC50 of 1 mg/kg.

Legend

Protein

Chemical

Disease

Primary Citation of related structures